



Aurobindo Pharma receives final approval for Risperidone Oral Solution

Aurobindo Pharma Limited is pleased to announce that it has received the final approval for Risperidone Oral Solution 1mg/mL (ANDA No. 78-452) from the US Food & Drug Administration (USFDA).

Risperidone Oral Solution 1mg/mL is generic equivalent to Risperdal® Oral Solution 1mg/mL of Ortho-McNeil Janssen. Risperidone Oral Solution is indicated in the treatment schizophrenia and falls under the neurological (CNS) segment. The product has a market size of approximately US\$ 68 million for the twelve months ending March 2009 according to Newport. The product will be launched shortly.

Aurobindo now has a total of 102 ANDA approvals (74 Final approvals and 28 Tentative approvals) from USFDA

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 100 countries..

For further information, please contact:

Investor Relations
Aurobindo Pharma Limited
Reg Off: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad
Phone: 040-66725000 / 66725401
Email: ir@aurobindo.com